BIRC5 and neoplasm: Therefore, the RNA inhibition designed against common regions of both the wild-type survivin and the survivin-deltaEx3 could be a more effective strategy for NSCLCs not only to improve the efficacy of chemo-radio therapy but also to suppress tumour cell proliferation (Li et al, 1998; Lu et al, 2004).